obesity drugs
obesity drugs
€50 Million Boost for GLP-1 Production in France!
🌟 Axplora invests €50M in France! 🏗️ Boosting GLP-1 manufacturing for diabetes and obesity therapies. 💊 Next-gen production by 2026! 🚀
Evotec and Partners Pioneer Breakthrough Obesity Drugs
✨ Evotec and partners aim to revolutionize obesity treatment with novel therapeutic targets. 🏥💊 Learn more about their collaboration!
Breakthrough Obesity Drug: 70 Achieve Over 15 Weight Loss
🌍 Roche's obesity drug CT-388 shows impressive results in clinical trial, offering hope for weight loss worldwide! 💊💪 ObesitySolution
Roche’s Breakthrough Obesity Drug: 188 Weight Loss!
🔍 Roche's CT-388 shows promising results in treating obesity, with a median weight loss of 18.8 in Phase I trial. 📈💊🩺
Scientists Discover Fat-Burning Breakthrough to Fight Obesity
📢 Researchers switch on brown fat cells, revolutionizing obesity research 🔥. Blocking enzyme AC3-AT helps combat obesity in mice. 💡👩🔬 Further research needed.
Novo Holdings Acquires Catalent for $165B Sells Sites for $11B: Tapping into Obesity and Diabetes Drug Market
📢 Novo Holdings acquires Catalent for $16.5B 💰 and sells 3 sites to Novo Nordisk for $11B 💼 to meet demand for obesity and diabetes drugs.
Roche Abandons AC Immune Collaboration Returns Drugs
📰 Roche's US subsidiary, Genentech, 🚢 jumps ship on AC Immune after disappointing study results. 🧪🔍 Crenezumab and Semorinemab returned. 💪 AC Immune remains focused on other therapies. 💰📅
Shocking FDA Investigation: Obesity Drugs Linked to Suicidal Thoughts
📢 FDA investigates suicide risk of obesity drugs semaglutide and tirzepatide, as well as hair loss and aspiration during surgery. Novo Nordisk and Eli Lilly cooperate.
